These data suggest that PRMT5 inhibition directly affected tumor cells but also reduced the antitumor activity of CD8 T cells, which may result from a higher expression of PD-L1 when tumor cell PRMT5 expression was inhibited. The gene discussed is CD8A; the disease is neoplasm.